Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezdiffra in Combination With Diabetes Therapies in MASH
NCT07848191Phase 4Recruiting
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Oct 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 4, open-label trial of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH) (6 arms), sponsored by Madrigal Pharmaceuticals. Primary endpoints: Number and Percentage of Participants With Treatment-Emergent Adverse Events at 28 weeks, Number and Percentage of Participants With TEAEs by Maximum Severity at 28 weeks and 1 more. Started Oct 2026; status: recruiting.
02
Drugs
resmetirom
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07848191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07848191.